Establishing Clinical Cutoffs for Response and Remission on the Screen for Child Anxiety Related Emotional Disorders (SCARED)

Abstract

<div class="section"> <a class="named-anchor" id="S1"> <!-- named anchor --> </a> <h5 class="section-title" id="d6519276e228">Objective</h5> <p id="P2">To determine optimal percent reduction and raw score cutoffs on the parent- and child-report Screen for Child Anxiety Related Emotional Disorders (SCARED) for predicting treatment response and remission among youth with anxiety disorders. </p> </div><div class="section"> <a class="named-anchor" id="S2"> <!-- named anchor --> </a> <h5 class="section-title" id="d6519276e233">Method</h5> <p id="P3">Data were from youth ( <i>N</i> = 438; ages 7–17 years) who completed treatment in the Child/Adolescent Anxiety Multimodal Study, a multi-site, randomized clinical trial that examined the relative efficacy of medication (sertraline), cognitive-behavioral therapy (Coping Cat), their combination, and pill placebo for the treatment of separation anxiety disorder, generalized anxiety disorder, and social phobia. The parent- and youth-report SCARED were administered at pre- and posttreatment. Quality receiver operating characteristic methods evaluated the performance of various SCARED percent reductions and absolute cutoff scores in predicting treatment response and remission, as defined by posttreatment ratings on the Clinical Global Impression scales and the Anxiety Disorders Interview Schedule. </p> </div><div class="section"> <a class="named-anchor" id="S3"> <!-- named anchor --> </a> <h5 class="section-title" id="d6519276e241">Results</h5> <p id="P4">Reductions of 55% on the SCARED-Parent and 50% on the SCARED-Youth optimally predicted treatment response. Posttreatment absolute raw scores of 10 (SCARED-Parent) and 12 (SCARED-Youth) optimally predicted remission in the total sample, though separate SCARED-Parent cutoffs for children (12–13) and adolescents (9) showed greatest quality of efficiency. Each cutoff significantly predicted response and remission at 6-month follow-up. </p> </div><div class="section"> <a class="named-anchor" id="S4"> <!-- named anchor --> </a> <h5 class="section-title" id="d6519276e246">Conclusion</h5> <p id="P5">Results serve as guidelines for operationalizing treatment response and remission on the SCARED, which may help clinicians systematically monitor treatment outcomes of youth with anxiety disorders in a cost- and time-efficient manner. </p> </div><div class="section"> <a class="named-anchor" id="S5"> <!-- named anchor --> </a> <h5 class="section-title" id="d6519276e251">Clinical trial registration information</h5> <p id="P6">Child and Adolescent Anxiety Disorders (CAMS); <a data-untrusted="" href="http://clinicaltrials.gov/" id="d6519276e255" target="xrefwindow">http://clinicaltrials.gov/</a>; NCT00052078. </p> </div>